SiSaf has developed the Bio-Courier® platform of silicon stabilized hybrid lipid nanoparticles to dramatically improve the stabilization and delivery of RNA based therapeutics and vaccines. We are using its proprietary next-generation hybrid nanoparticles to advance our in-house pipeline of RNA therapeutics for rare genetic skeletal disorders, alongside partnering with specialty pharmaceutical companies to maximize the potential applications of its Bio-Courier platform.
Being a bioabsorbable silicon-lipid hybrid, Bio-Couriers, optimize the delivery of nucleic acid-based therapeutics, through superior stability and protection of the RNA payload and lipid surface while reducing the potential of adverse immune events.
Founded by entrepreneur and leading biomaterials specialist Dr Suzanne Saffie-Siebert, SiSaf is headquartered in Guildford, UK, with fully integrated state-of-the-art research labs, pilot manufacturing and bioanalytical facilities.
SiSaf is a private company supported by venture capital investors including Vickers Venture Partners & UK Future Fund.
The company’s Founder and CEO, Dr Suzanne Saffie-Siebert, had the vision of a new generation of hybrid drug delivery technology that would combine lipid nanoparticles with biodegradable silicon. This vision was rooted in years of experience with both liposomes and silicon, having completed her PhD thesis on the incorporation of plasmid DNA into liposomes and having helped pioneer drug delivery with porous silicon at pSiMedica, a spin-out of Qinetiq. She hypothesized that silicon could be used to stabilize lipid nanoparticles and that in turn lipids would help control the biodegradation of Silicon. With this vision, SiSaf began operating in 2008 with funding from Invest NI and the investment arm of the University of Ulster.
Over its foundational years the team was dedicated to developing and optimising the new hybrid technology and generating safety and efficacy data. These data enabled SiSaf in 2016 to secure Series A funding to pivot from a University-based pre-seed company to an emerging biopharma company commercialising its RNA delivery technology.
The company also formed a partnership with Croda International plc and launched a skincare subsidiary in the U.S.
In 2019, the company focused its R&D activities on gene-based medicines with a pipeline developed through a partnership with Avellino Labs USA to co-develop topical gene therapies for corneal dystrophies, and entered into a license and research agreement with the University of L’Aquila, Italy, for the development of siRNA therapies for rare skeletal diseases.
SiSaf has a fantastic opportunity to develop and commercialise its Bio-Courier technology for a range of therapies, but particularly its potential in gene therapy. As an experienced finance professional, it is great to be able to work with Suzanne and the team to realise that value growth.
Distinguished Professor of Medicine and Medical and Molecular Genetics and is the director of the division of Endocrinology and Metabolism. Indianan University School of Medicine
Frost Professor of Ophthalmology and Chairman of the Academic Department of Ophthalmology at St. Thomas’ Hospital
I led the Series A investment in SiSaf not just because of their innovative platform technology, but also the passion of the people behind it.